These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 16723576)
41. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801 [TBL] [Abstract][Full Text] [Related]
42. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. Hayden MK; Rezai K; Hayes RA; Lolans K; Quinn JP; Weinstein RA J Clin Microbiol; 2005 Oct; 43(10):5285-7. PubMed ID: 16207998 [TBL] [Abstract][Full Text] [Related]
43. Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS. Berscheid A; François P; Strittmatter A; Gottschalk G; Schrenzel J; Sass P; Bierbaum G J Antimicrob Chemother; 2014 Dec; 69(12):3190-8. PubMed ID: 25103491 [TBL] [Abstract][Full Text] [Related]
44. In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates. Anastasiou DM; Morgan M; Ruane PJ; Steenbergen JN; Katz BD; Alder JD; Thorne GM Diagn Microbiol Infect Dis; 2008 Jul; 61(3):339-42. PubMed ID: 18304772 [TBL] [Abstract][Full Text] [Related]
45. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Sader HS; Jones RN Clin Infect Dis; 2006 Sep; 43(6):798-9; author reply 799-800. PubMed ID: 16912964 [No Abstract] [Full Text] [Related]
46. Alanyl-phosphatidylglycerol and lysyl-phosphatidylglycerol are translocated by the same MprF flippases and have similar capacities to protect against the antibiotic daptomycin in Staphylococcus aureus. Slavetinsky CJ; Peschel A; Ernst CM Antimicrob Agents Chemother; 2012 Jul; 56(7):3492-7. PubMed ID: 22491694 [TBL] [Abstract][Full Text] [Related]
47. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. Yang SJ; Kreiswirth BN; Sakoulas G; Yeaman MR; Xiong YQ; Sawa A; Bayer AS J Infect Dis; 2009 Dec; 200(12):1916-20. PubMed ID: 19919306 [TBL] [Abstract][Full Text] [Related]
48. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Fluit AC; Schmitz FJ; Verhoef J; Milatovic D Int J Antimicrob Agents; 2004 Jul; 24(1):59-66. PubMed ID: 15225863 [TBL] [Abstract][Full Text] [Related]
49. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Saravolatz LD; Pawlak J; Johnson LB; Saravolatz LD; Husain N Int J Antimicrob Agents; 2010 Nov; 36(5):478-80. PubMed ID: 20846830 [No Abstract] [Full Text] [Related]
50. dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus. Cafiso V; Bertuccio T; Purrello S; Campanile F; Mammina C; Sartor A; Raglio A; Stefani S Int J Antimicrob Agents; 2014 Jan; 43(1):26-31. PubMed ID: 24183798 [TBL] [Abstract][Full Text] [Related]
52. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Entenza JM; Giddey M; Vouillamoz J; Moreillon P Int J Antimicrob Agents; 2010 May; 35(5):451-6. PubMed ID: 20185277 [TBL] [Abstract][Full Text] [Related]
54. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. Kelley PG; Gao W; Ward PB; Howden BP J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156 [TBL] [Abstract][Full Text] [Related]
55. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Sakoulas G; Alder J; Thauvin-Eliopoulos C; Moellering RC; Eliopoulos GM Antimicrob Agents Chemother; 2006 Apr; 50(4):1581-5. PubMed ID: 16569891 [TBL] [Abstract][Full Text] [Related]
56. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Moise PA; North D; Steenbergen JN; Sakoulas G Lancet Infect Dis; 2009 Oct; 9(10):617-24. PubMed ID: 19778764 [TBL] [Abstract][Full Text] [Related]
57. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Johnson AP; Mushtaq S; Warner M; Livermore DM Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254 [TBL] [Abstract][Full Text] [Related]
58. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Julian K; Kosowska-Shick K; Whitener C; Roos M; Labischinski H; Rubio A; Parent L; Ednie L; Koeth L; Bogdanovich T; Appelbaum PC Antimicrob Agents Chemother; 2007 Sep; 51(9):3445-8. PubMed ID: 17620372 [TBL] [Abstract][Full Text] [Related]
59. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Patel JB; Jevitt LA; Hageman J; McDonald LC; Tenover FC Clin Infect Dis; 2006 Jun; 42(11):1652-3. PubMed ID: 16652325 [No Abstract] [Full Text] [Related]
60. Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence. Stefani S; Campanile F; Santagati M; Mezzatesta ML; Cafiso V; Pacini G Int J Antimicrob Agents; 2015 Sep; 46(3):278-89. PubMed ID: 26143590 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]